Details for New Drug Application (NDA): 217780

NDA 217780 describes GUAIFENESIN, which is a drug marketed by Actavis Labs Fl, Amneal Pharms, Aurobindo Pharma, Dr Reddys, Granules, Guardian Drug, Marksans Pharma, Ohm Labs Inc, Perrigo R And D, Sun Pharm, Aurobindo Pharma Ltd, L Perrigo Co, and Sun Pharm Inds Inc, and is included in twenty-one NDAs. It is available from seventy-nine suppliers. Additional details are available on the GUAIFENESIN profile page.

The generic ingredient in GUAIFENESIN is guaifenesin; pseudoephedrine hydrochloride. There are twenty drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the guaifenesin; pseudoephedrine hydrochloride profile page.

Summary for 217780

Tradename:	GUAIFENESIN
Applicant:	Marksans Pharma
Ingredient:	guaifenesin
Patents:	0

Pharmacology for NDA: 217780

Physiological Effect

Decreased Respiratory Secretion Viscosity Increased Respiratory Secretions

Medical Subject Heading (MeSH) Categories for 217780

Expectorants

Suppliers and Packaging for NDA: 217780

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
GUAIFENESIN	guaifenesin	TABLET, EXTENDED RELEASE;ORAL	217780	ANDA	MARKSANS PHARMA LIMITED	25000-041	25000-041-12	500 TABLET in 1 BOTTLE (25000-041-12)
GUAIFENESIN	guaifenesin	TABLET, EXTENDED RELEASE;ORAL	217780	ANDA	MARKSANS PHARMA LIMITED	25000-041	25000-041-75	2 BLISTER PACK in 1 CARTON (25000-041-75) / 6 TABLET in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:	OTC	Dosage:	TABLET, EXTENDED RELEASE;ORAL			Strength	600MG
Approval Date:	Aug 21, 2023	TE:		RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	OTC	Dosage:	TABLET, EXTENDED RELEASE;ORAL			Strength	1.2GM
Approval Date:	Aug 21, 2023	TE:		RLD:	No

Complete Access Available with Subscription